Biomedical subjects

K Fehr

Publications and source records attributed to K Fehr.

78 records · Page 5Linked to original sources

PubMedDate not supplied

Inhibition of human lysosomal elastase by the cartilage bone marrow extract Rumalon.

Human lysosomal elastase from polymorphonuclear leucocytes is inhibited by the cartilage bone marrow extract Rumalon. Separately, both the cartilage and the bone marrow extracts are able to inhibit the enzymatic activity by 73%, under saturating conditions. The mixture of the two extracts inhibits elastase by 93%. It is suggested that the two partners act as a cumulative inhibition mechanism and this phenomenon is emphasized in a general theoretical model for synergy of proteinase-directed inhibitors.

Arthritis, Rheumatoid↗

PubMedDate not supplied

[Appearance of giant cell arteritis 6 years after the 1st manifestation of polymyalgia rheumatica].

A case of polymyalgia rheumatica in a 70 year old woman is described. The patient was treated for 6 years with corticosteroids. Seven months after withdrawal of treatment, a severe relapse of polymyalgia rheumatica appeared which was connected with a histologically and immunohistochemically proved temporal arteritis. The problem of the duration of steroid treatment and the need for continued clinical as well as laboratory follow-up after withdrawal of therapy are discussed.

Aged↗

PubMedDate not supplied

[Morphological studies of the reparative function of pannus tissue in experimental arthritis in rabbits].

Histologic and electron microscopic studies of inflammatory pannus tissue induced experimentally in the knee joint of rabbits revealed not only destructive but also repair features. Thus, in addition to its chondrolytic and osteolytic properties the pannus exhibits marked fibroblastic activity resulting in fibrosis of its superficial part. At the same time activation of chondrocytes is observed.

Animals↗

PubMedDate not supplied

Effect of antirheumatic drugs on cathepsin B1 from bovine spleen.

The inhibitory effect on cathepsin B1 of 39 antirheumatic and other agents has been studied. The enzyme was purified from bovine spleen (specific activity 2.8 units/ml/E280 unit) and the effect of the drugs measured by determining the decrease of enzyme activity towards BANA as substrate. Analgesics, antimalarials, cytostatic agents, steroids as well as d-penicillamine, colchicine, allopurinol, chlorzoxazone and chlorpromazine either had no effect on cathepsin B1 or inhibited it to a very small extent. Typical anti-inflammatory and antirheumatic agents like gold and pyrazolone derivatives (with the exception of sulfinpyrazone) suppressed the activity of the enzyme at a concentration of 10(-6) M. Two others, indomethacin and diclofenac, suppressed it at a concentration of 10(-5) M. Two sulfonated polysaccharides, arteparon and pentosan polysulfate (SP54), were also potent inhibitors. Salicylates, however, inhibited cathepsin B1 only at much higher concentrations (10(-2) M. Higher concentrations of cysteine (2 mM) decreased the inhibitory effect of some otherwise effective drugs. Inhibition of cathepsin B1 may be one way in which some of the drugs tested exercise their therapeutic effect in rheumatic diseases.

Animals↗

PubMedDate not supplied

[Ankylosing spondylitis (Bechterew) and tissue antigen HLA-B 27. II. HLA-B 27 negativity in classical clinical ankylosing spondylitis: no independent nosological entity].

The question, whether HLA-B27-negative patients with classical ankylosing spondylitis (AS) belong to a separate nosological entity, was studied by a standardized analysis of 12 clinical, 8 radiological and 6 laboratory criteria in 95 cases, including 7 with HLA-B27-negativity, who reinforced international criteria for classical AS. The results showed neither definite clinical nor radiological, or laboratory differences between the HLA-B27 negative and positive group. We conclude, that existence or absence of the tissue antigen HLA-B27 has no influence on inflammatory activity of skeletal or soft tissue manifestations of the disease. The group of HLA-B27-negative patients who fulfill the criteria of classical AS does therefore not seem to form a separate nosological entity.

HLA Antigens↗

PubMedDate not supplied

[Ankylosing spondylitis (Bechterew) and tissue antigen HLA-B 27. I. Diagnostic value of HLA-typing].

In 95 Swiss patients with classical ankylosing spondylitis (AS) the tissue antigen HLA-B27 was present in 92.6%, compared with 7.7% in healthy Swiss blood donors. Assuming the prevalence of ankylosing spondylitis in Switzerland to be 1.9 promille, the chance of a Swiss carrier of HLA-B27 to develop a classical form of AS would be only some 2.2%. For diagnostic purposes, HLA typing thus seems to be of very little value, as among the 462 000 Swiss carriers of HLA-B27 there seem to exist no more than 10 800 classical cases with clinically manifest AS. Absence of HLA-B 27 does not exclude ankylosing spondylitis, as 7.4% of the classical cases are HLA-B27-negative. However, the crudely calculated risk to develop AS is 160 times smaller compared to a carrier HLA-B27. Corner stone of the diagnosis therefore remains careful case history and radiological features of a bilateral sacroileitis of at least grade II.

Adolescent↗